The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

The FDA said Ozempic can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

It showed that 1 mg Ozempic led to a 24 per cent reduced risk of worsening kidney disease and kidney failure (end-stage kidney disease)

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common complication of type 2 diabetes.

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients with type 2 diabetes and chronic kidney disease.

After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still appears to be in limbo.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Currently, Rilparencel’s Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that’s suitable for the FDA. The FDA confirmed in ... 2 diabetes [T2DM] patients at risk of kidney failure. Nonetheless, I do believe it ...